Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Biotechwantabe who wrote (3304)	6/9/2021 4:42:12 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 3557

<Still a 15p/e on 30% plus growth is ridiculous.> Due to COVID 2Q growth will spike to 30%, however regular growth rate at REGN is ~10-15%! Still, PE should be higher. Concern over Eylea further growth (or decline if E-generic enter market, with very big IF) is hanging on on stock price for last 3 years. REGN NEEDS cancer franchise growth, and unfortunately, post-ASCO conference did not relieve anything. I do not like when Yan skip direct respond to Qs, it is not good for "scientific reputation"!